Atropina em baixas doses na redução da progressão da miopia em crianças e adolescentes

• DOI: https://doi.org/10.22533/at.ed.8631825010813

• Palavras-chave: Miopia; Atropina; Progressão da Doença; Refratometria; Acuidade Visual.

• Keywords: Myopia; Atropine; Disease Progression; Refractometry; Visual Acuity.

• Abstract: Myopia occurs when there is an excessive elongation of the axial length of the eye, and it is the most common refractive error in the world, being considered a global epidemic that primarily affects children and adolescents. This study aims to evaluate the efficacy of using low-dose atropine eye drops in controlling the progression of myopia, especially in myopic children and adolescents. A search for studies was conducted on the National Library of Medicine (PubMed) and Virtual Health Library Regional Portal (BVS) platforms using the descriptors 'myopia,' 'atropine,' and 'progression,' and a total of 27 scientific articles were included in this study after applying the inclusion criteria: articles published in the last 5 years (2019 to 2024), with full-text available, and whose studies were of the controlled clinical trial and observational study types. Articles that lacked theoretical and thematic support aligned with the objective of this study, articles outside the topic, and articles that were duplicated in the two databases used were excluded. Based on the analyzed studies, it was observed that the most evaluated dose of atropine was 0.01%, considered a low dose. Low-dose atropine eye drops, such as 0.01% and 0.05%, demonstrated safety and presented fewer adverse effects, unlike high-dose atropine. Therefore, it is concluded that low-dose atropine eye drops are safe and effective in controlling the progression of myopia in myopic children and adolescents.